A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Safety Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of EP-7041 in Healthy Subjects
Latest Information Update: 21 Sep 2020
At a glance
- Drugs EP 7041 (Primary)
- Indications Thrombosis
- Focus Adverse reactions; First in man
- Sponsors eXIthera Pharmaceuticals
- 17 Sep 2020 Results presented in an eXIthera Pharmaceuticals media release.
- 17 Sep 2020 According to an eXIthera Pharmaceuticals media release, data from this trial were publication in Critical Care Explorations.
- 15 Nov 2017 Results (n=8) assessing safety, tolerability, pharmacokinetics and pharmacodynamics presented at the 90th Annual Scientific Sessions of the American Heart Association.